We have read with great interest the letter to the editor by Faul et al regarding our recently published manuscript.
First, Faul et al indicate that our study demonstrated an improvement in functional class. Although it is true that, as we reported, the New York Heart Association functional class improved at follow-up, this was not the primary end point and is the variable subject to significant observer bias, not to mention placebo effect (neither investigators nor patients were blinded to the treatment). More important, the prespecified primary end point, an objective assessment of functional capacity (6-Minute Walking Distance [6MWD]), did not demonstrate any improvements nor were there any favorable changes in several parameters assessing the patients' dyspnea and quality of life (St George Respiratory Questionnaire, Modified Medical Research Council Dyspnea Scale, Borg Scale, and Bode Index). 1 Second, Faul et al indicate that it would be premature to conclude that the creation of an arteriovenous fistula does not improve walking distance and that the absence of a decline in walking distance may be considered a success. It is important to state, once again, that the 6MWD did not improve. In fact, as Faul et al correctly state, there was a trend toward a decline in walking distance by 44 m (Pϭ0.07). 1 Although a more rapid decline in patients treated conventionally is conceivable, it would be incorrect to consider this result a success in the absence of control group data. Faul et al report that, in their unpublished experience of 180 patients with chronic obstructive pulmonary disease who underwent arteriovenous fistula creation, a range of benefits (eg, regaining the ability to wash and dress without assistance, carrying groceries, and playing with grandchildren) occurred; however, they failed to quantify these observations or provide any additional objective performance parameters supporting a benefit. Faul et al hypothesize that the failure to improve the 6MWD may be the consequence of lower extremity edema, thereby counteracting any potential benefits. As indicated in our recent article, 1 lower extremity edema was common. Indeed, it may hinder the patients' ability to walk, a concerning additional problem that is not desirable in patients whose mobility is compromised to begin with. In fact, it may be the consequence of right-sided heart failure that could be the result of additional strain caused by high output on an already compromised right ventricle.
Third, Faul et al address our observed rate of venous stenosis and deep venous thrombosis (46% and 27%, respectively) and indicate that, in their experience, the stenoses are best treated by venous stenting to prevent thrombosis, rather than by venous balloon angioplasty or fistula closure. However, they fail to provide us with any information on the number of patients who experienced deep venous thrombosis or stenosis or long-term patency rates after self-expanding venous stenting, either in their described unpublished experience with 180 patients or in their previously published study of 12 patients with predominantly surgical creation of an arteriovenous fistula. 2 Whether the fistula itself is the cause of venous stenosis and thrombosis or the resulting altered venous flow characteristics, the consequences are the same and equally serious.
Finally, Faul et al stress the hemodynamic changes and the increase in oxygen delivery. It is true and not surprising that fistula creation increases cardiac output and total oxygen delivery. How-ever, the most pertinent issue is not addressed in their Letter to the Editor or in their previously published experience: it remains a hypothesis that the increase in overall cardiac output and oxygen delivery actually translates into improvement in tissue oxygen delivery, which is the more important parameter than overall oxygen delivery, because much of the increased cardiac output and oxygen is not delivered to the tissue but circulates through the fistula. In fact, when, after experimental creation of a fistula, blood flow specifically through the fistula and to the remainder of the body (tissue flow) is measured in an animal model, the cardiac output increases. However, this overall increase in cardiac output is accompanied by a significant reduction in tissue flow, perhaps the consequence of the much lower resistance to flow through the fistula into the venous side. 3 To conclude, although we demonstrated that percutaneous creation of an arteriovenous fistula is technically feasible and is accompanied by an increase in cardiac output, overall oxygen delivery, and New York Heart Association class, it was followed by an unfavorable trend toward a reduction in 6MWD, the prespecified primary end point, and absence of an improvement in measures of quality of life and dyspnea. In addition, there were an alarming number of potentially serious adverse events, the successful management of which remains to be demonstrated. It should stimulate re-evaluation of the physiological basis for the concept of arteriovenous fistula creation in patients with chronic obstructive pulmonary disease. Finally, it should not be recommended in the absence of further data demonstrating its safety and favorable risk/benefit ratio. We thank Faul et al for their interest and eagerly await the publication of their experience.
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